Skip to main content
TipRanks
Go Ultimate75% OFF

Vicore Pharma Holding AB (6Y4) Stock Forecast & Price Target

3 Followers
See the Price Targets and Ratings of:

6Y4 Analyst Ratings

Moderate Buy
1Ratings
1Buy0Hold0Sell
Based on 1 analysts giving stock ratings to Vicore Pharma Holding AB in the past 3 months

6Y4 Stock 12 Month Forecast

€3.52▲(248.34% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Vicore Pharma Holding AB in the last 3 months. The average price target is EUR 3.52 with a high forecast of EUR 3.52 and a low forecast of EUR 3.52. The average price target represents a 248.34% change from the last price of EUR 1.01.
Highest Price Target€3.52Average Price Target€3.52Lowest Price Target€3.52

Detailed List of Analyst Forecasts​

Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
Analyst forecasts for DE:6Y4
Price TargetArticle
Guggenheim Analyst forecast on DE:6Y4Unknown AnalystNot RankedGuggenheim€3.43→€3.52buy248.34%UpsideReiterated11/05/26
Cantor Fitzgerald€2.98buy194.75%UpsideInitiated06/08/26
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
HROWHarrow Health
PLSEPulse Biosciences
DFTXDefinium Therapeutics
IMUXImmunic
MDWDMediwound

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vicore Pharma Holding AB

3 Months
Vamil Divan
Vamil DivanGuggenheim
Success Rate3/3 ratings generated profit
100%
Average Return
+7.23%

Copying Vamil Divan's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +7.23% per trade.

1 Year
Vamil Divan
Vamil DivanGuggenheim
Success Rate3/3 ratings generated profit
100%
Average Return
+9.23%

Copying Vamil Divan's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +9.23% per trade.

2 Years
Vamil Divan
Vamil DivanGuggenheim
Success Rate3/3 ratings generated profit
100%
Average Return
+9.23%

Copying Vamil Divan's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +9.23% per trade.

6Y4 Analyst Recommendation Trends

01234Dec 25Jan 26Feb 26Mar 26Apr 26May 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26
Monthly rating counts for 6Y4
RatingJul 26Aug 26Sep 26Oct 26Nov 26
Strong Buy22111
Buy00000
Hold00000
Sell00000
Strong Sell00000
total22111

In the current month, 6Y4 has received 1 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 6Y4 average Analyst price target in the past 3 months is 3.52.

6Y4 Financial Forecast

€-2€-1.5€-1€-0.5€0Q1 2026Q3 2026Q4 2026
High€-0.04
Consensus€-0.05
Low€-0.05

6Y4 Earnings Forecast

Next quarter’s earnings estimate for 6Y4 is -EUR 0.05 with a range of -EUR 0.05 to -EUR 0.04. The previous quarter’s EPS was -EUR 0.04. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.

€-1€50,208.5€100,418€150,627.5€200,837Q1 2026Q3 2026Q4 2026
High€182K
Consensus€73.1K
Low€0.00

6Y4 Sales Forecast

Next quarter’s sales forecast for 6Y4 is EUR 73.06K with a range of EUR 0 to EUR 181.51K. The previous quarter’s sales results were EUR 53.91K. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.

6Y4 Stock Forecast FAQ

What is DE:6Y4’s average 12-month price target, according to analysts?
Based on analyst ratings, Vicore Pharma Holding AB’s 12-month average price target is €3.52.
What is DE:6Y4’s upside potential, based on the analysts’ average price target?
Vicore Pharma Holding AB has 248.34% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Vicore Pharma Holding AB a Buy, Sell or Hold?
Vicore Pharma Holding AB has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
What is Vicore Pharma Holding AB’s share price target?
The average share price target for Vicore Pharma Holding AB is €3.52. This is based on 1 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is €3.52, and the lowest forecast is €3.52. The average share price target represents a 248.34% increase from the current price of €1.01.
What do analysts say about Vicore Pharma Holding AB?
Vicore Pharma Holding AB’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Street analysts.
How can I buy shares of Vicore Pharma Holding AB?
To buy shares of DE:6Y4, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.